Therapeutic proteins and antibodies: from design to function


Wednesday, 18 June 2014

Cineworld: The O2, London, SE10 0DX, UK

This meeting  discusses new developments in therapeutic protein and antibody engineering with specific focus on science and technology of modifying proteins and antibodies (and the conditions of their manufacture) toward specific predefined properties that allow them to act as effective biological drugs. Special emphasis will be placed on structure-function relationships, mechanisms of action, potency and efficacy in disease-relevant models and in clinical trials. There will be plenty of opportunity for discussion and debate addressing the wide range of disciplines applied to the rapid and economical production of these molecules for biological therapies

This event has CPD accreditation

Meeting chair: Dr Sophia Karagiannis , Senior Research Fellow in Translational Cancer Immunology, Head of Cancer Antibody Discovery and Immunotherapy, King’s College London School of Medicine, UK


Who Should Attend

All academic and biotechnology/biopharma professionals interested in biological protein and antibody engineering, functional and potency evaluations; also scientists interested in biological therapeutics mechanisms of action and translational implications for therapy.

The Deadline for abstract submissions for oral presentation is April 10th 2014

Abstracts for poster presentation only can be submitted up to two weeks before the event

You can download the instructions for authors at


Latest Euroscicon Tweets

Error: You currently have access to a subset of Twitter API v2 endpoints and limited v1.1 endpoints (e.g. media post, oauth) only. If you need access to this endpoint, you may need a different access level. You can learn more here: